Literature DB >> 1059384

Organ irradiation and combination chemotherapy in treatment of acute lymphocytic leukaemia in children.

P Lanzkowsky, A Shende, I Aral, G Saluja.   

Abstract

Lanzkowsky, P., Shende, A., Aral, I., Saluja, G. (1975). Archives of Disease in Childhood, 50, 685. Organ irradiation and combination chemotherapy in treatment of acute lymphocytic leukaemia in children. A total of 30 consecutive children with acute lymphocytic leukaemia (ALL) were treated from June 1971 until December 1974. Remission was induced with the use of vincristine and prednisone. After induction of remission, cranial irradiation and intrathecal methotrexate were given. Then the liver, spleen, and kidney were irradiated and 6-mercaptopurine, cyclophosphamide, and methotrexate were administered during the maintenance phase. Pulsed doses of vincristine and prednisone were administered at 10- to 12-week intervals. The patients were subdivided into two groups based on their initial white blood cell (WBC) counts: a standard risk group with an initial WBC count of less than 25 000/mm3 (25 X 10(9)/1) and a high risk group with an initial WBC count greater than 25 000/mm3 (25 X 10(9)/1). Of the 30 children entered in this study one standard risk patient died in the induction phase before attaining remission. Analysis of the results is therefore based on the remaining 29 patients, 22 standard risk and 7 high risk patients, who attained complete remission. Survival rates in continuous remission were found to be 43% of the high risk group, 88% for the standard risk group, and 77% for the combined group. Analysis of the data indicates that this therapy is unsatisfactory in high risk ALL. The results to date of this therapy for standard risk are sufficiently encouraging to continue its use in this subgroup of patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1059384      PMCID: PMC1545634          DOI: 10.1136/adc.50.9.685

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  THE PERSISTENCE OF EXTRAMEDULLARY LEUKEMIC INFILTRATES DURING BONE MARROW REMISSION OF ACUTE LEUKEMIA.

Authors:  B A NIES; G P BODEY; L B THOMAS; G BRECHER; E J FREIREICH
Journal:  Blood       Date:  1965-08       Impact factor: 22.113

2.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

3.  Letter: Absence of pectoralis major muscle in association with acute leukemia.

Authors:  P Lanzkowsky
Journal:  J Pediatr       Date:  1975-05       Impact factor: 4.406

4.  Fatalities during remission of childhood leukemia.

Authors:  J V Simone; E Holland; W Johnson
Journal:  Blood       Date:  1972-06       Impact factor: 22.113

5.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia.

Authors:  R J Aur; J Simone; H O Hustu; T Walters; L Borella; C Pratt; D Pinkel
Journal:  Blood       Date:  1971-03       Impact factor: 22.113

6.  Acute leukemia presenting as laryngeal obstruction.

Authors:  M Ti; R Villafuerte; P H Chase; H Dosik
Journal:  Cancer       Date:  1974-08       Impact factor: 6.860

7.  Oncologists' reply: survival expectancy in acute lymphocytic leukemia.

Authors:  J F Holland; O Glidewell
Journal:  N Engl J Med       Date:  1972-10-12       Impact factor: 91.245

8.  A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia.

Authors:  R J Aur; J V Simone; H O Hustu; M S Verzosa
Journal:  Cancer       Date:  1972-02       Impact factor: 6.860

9.  The analysis of clinical trails in leukaemia.

Authors:  M C Pike
Journal:  Recent Results Cancer Res       Date:  1973

10.  Problems in the evaluation of long-term results.

Authors:  M Karon
Journal:  Recent Results Cancer Res       Date:  1973
View more
  1 in total

1.  Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model.

Authors:  Susan J Zunino; David H Storms; John W Newman; Theresa L Pedersen; Carl L Keen; Jonathan M Ducore
Journal:  Int J Oncol       Date:  2011-12-22       Impact factor: 5.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.